Trade Better Therapeutics, Inc. - BTTX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0562 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.6683 |
Open* | 0.6671 |
1-Year Change* | -67.3% |
Day's Range* | 0.6486 - 0.7027 |
52 wk Range | 0.59-2.80 |
Average Volume (10 days) | 135.87K |
Average Volume (3 months) | 2.90M |
Market Cap | 21.89M |
P/E Ratio | -100.00K |
Shares Outstanding | 31.73M |
Revenue | N/A |
EPS | -1.67 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Aug 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 0.6830 | 0.0159 | 2.38% | 0.6671 | 0.7263 | 0.6480 |
May 25, 2023 | 0.6683 | -0.0257 | -3.70% | 0.6940 | 0.7422 | 0.6483 |
May 24, 2023 | 0.7168 | -0.0290 | -3.89% | 0.7458 | 0.7459 | 0.6924 |
May 23, 2023 | 0.7507 | 0.0054 | 0.72% | 0.7453 | 0.7651 | 0.7453 |
May 22, 2023 | 0.7555 | 0.0201 | 2.73% | 0.7354 | 0.7942 | 0.7354 |
May 19, 2023 | 0.7564 | 0.0013 | 0.17% | 0.7551 | 0.7747 | 0.7540 |
May 18, 2023 | 0.7554 | -0.0015 | -0.20% | 0.7569 | 0.7845 | 0.7356 |
May 17, 2023 | 0.7582 | 0.0126 | 1.69% | 0.7456 | 0.7797 | 0.7456 |
May 16, 2023 | 0.7620 | -0.0388 | -4.85% | 0.8008 | 0.8037 | 0.7260 |
May 15, 2023 | 0.7457 | -0.0580 | -7.22% | 0.8037 | 0.8136 | 0.7359 |
May 12, 2023 | 0.7470 | 0.0310 | 4.33% | 0.7160 | 0.7749 | 0.7159 |
May 11, 2023 | 0.7555 | -0.0823 | -9.82% | 0.8378 | 0.8571 | 0.7257 |
May 10, 2023 | 0.8349 | 0.0215 | 2.64% | 0.8134 | 0.8716 | 0.7544 |
May 9, 2023 | 0.8039 | 0.0391 | 5.11% | 0.7648 | 0.8137 | 0.7262 |
May 8, 2023 | 0.7746 | -0.1165 | -13.07% | 0.8911 | 0.8911 | 0.6907 |
May 5, 2023 | 0.9005 | 0.0042 | 0.47% | 0.8963 | 0.9298 | 0.8905 |
May 4, 2023 | 0.9297 | -0.1353 | -12.70% | 1.0650 | 1.0653 | 0.8708 |
May 3, 2023 | 1.0750 | 0.0017 | 0.16% | 1.0733 | 1.1041 | 1.0635 |
May 2, 2023 | 1.0944 | 0.0095 | 0.88% | 1.0849 | 1.1233 | 1.0652 |
May 1, 2023 | 1.0943 | -0.0281 | -2.50% | 1.1224 | 1.1332 | 1.0741 |
Better Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, August 9, 2023 | ||
Time (UTC) 20:00 | Country US
| Event Q2 2023 Better Therapeutics Inc Earnings Release Q2 2023 Better Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Time (UTC) 21:00 | Country US
| Event Q3 2023 Better Therapeutics Inc Earnings Release Q3 2023 Better Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | |
---|---|---|---|
Total revenue | 0 | 0 | 0 |
Total Operating Expense | 38.262 | 40.303 | 0.00169 |
Other Operating Expenses, Total | 0.00169 | ||
Operating Income | -38.262 | -40.303 | -0.00169 |
Net Income Before Taxes | -39.753 | -40.488 | -0.00169 |
Net Income After Taxes | -39.76 | -40.335 | -0.00169 |
Net Income Before Extra. Items | -39.76 | -40.335 | -0.00169 |
Net Income | -39.76 | -40.335 | -0.00169 |
Income Available to Common Excl. Extra. Items | -39.76 | -40.335 | -0.00169 |
Income Available to Common Incl. Extra. Items | -39.76 | -40.335 | -0.00169 |
Diluted Net Income | -39.76 | -40.335 | -0.00169 |
Diluted Weighted Average Shares | 23.5578 | 23.6027 | 7.5575 |
Diluted EPS Excluding Extraordinary Items | -1.68776 | -1.70891 | -0.00022 |
Dividends per Share - Common Stock Primary Issue | 0 | ||
Diluted Normalized EPS | -1.68776 | -1.4406 | -0.00022 |
Selling/General/Admin. Expenses, Total | 21.822 | 11.124 | |
Research & Development | 16.44 | 19.436 | |
Unusual Expense (Income) | 0 | 9.743 | |
Interest Income (Expense), Net Non-Operating | -1.491 | -0.185 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 8.925 | 8.322 | 10.996 | 9.599 | 9.345 |
Other Operating Expenses, Total | |||||
Operating Income | -8.925 | -8.322 | -10.996 | -9.599 | -9.345 |
Interest Income (Expense), Net Non-Operating | -0.431 | -0.439 | -0.406 | -0.329 | -0.317 |
Net Income Before Taxes | -9.356 | -8.761 | -11.402 | -9.928 | -9.662 |
Net Income After Taxes | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Net Income Before Extra. Items | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Net Income | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Income Available to Common Excl. Extra. Items | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Income Available to Common Incl. Extra. Items | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Diluted Net Income | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Diluted Weighted Average Shares | 23.8266 | 23.6315 | 23.6931 | 23.593 | 23.4132 |
Diluted EPS Excluding Extraordinary Items | -0.39271 | -0.3709 | -0.48136 | -0.4208 | -0.41267 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.39271 | -0.3709 | -0.48136 | -0.4208 | -0.41267 |
Selling/General/Admin. Expenses, Total | 5.536 | 5.273 | 5.519 | 5.358 | 5.672 |
Research & Development | 3.389 | 3.049 | 5.477 | 4.241 | 3.673 |
Unusual Expense (Income) | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | |
---|---|---|---|
Total Current Assets | 18.446 | 45.251 | 0.08666 |
Cash and Short Term Investments | 15.74 | 40.566 | 0.02476 |
Cash | 0.02476 | ||
Other Current Assets, Total | 0.21 | 0.276 | 0.06189 |
Total Assets | 22.943 | 50.958 | 0.08666 |
Total Current Liabilities | 13.494 | 4.733 | 0.06334 |
Accrued Expenses | 5.927 | 3.21 | 0.00145 |
Notes Payable/Short Term Debt | 0 | 0 | 0.06189 |
Total Liabilities | 23.842 | 14.238 | 0.06334 |
Total Long Term Debt | 10.348 | 9.505 | 0 |
Total Equity | -0.899 | 36.72 | 0.02331 |
Common Stock | 0.002 | 0.002 | 0.00014 |
Additional Paid-In Capital | 110.602 | 108.461 | 0.02486 |
Retained Earnings (Accumulated Deficit) | -111.503 | -71.743 | -0.00169 |
Total Liabilities & Shareholders’ Equity | 22.943 | 50.958 | 0.08666 |
Total Common Shares Outstanding | 23.851 | 23.6027 | 7.5575 |
Cash & Equivalents | 15.74 | 40.566 | |
Prepaid Expenses | 2.496 | 4.409 | |
Property/Plant/Equipment, Total - Net | 0.121 | 0.082 | |
Intangibles, Net | 3.888 | 5.077 | |
Other Long Term Assets, Total | 0.488 | 0.548 | |
Accounts Payable | 3.035 | 1.523 | |
Long Term Debt | 10.348 | 9.505 | |
Property/Plant/Equipment, Total - Gross | 0.178 | ||
Accumulated Depreciation, Total | -0.057 | ||
Current Port. of LT Debt/Capital Leases | 4.532 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 8.442 | 18.446 | 23.49 | 32.137 | 35.179 |
Cash and Short Term Investments | 6.068 | 15.74 | 22.305 | 29.685 | 31.673 |
Cash | |||||
Prepaid Expenses | 1.968 | 2.496 | 1.123 | 2.38 | 3.242 |
Total Assets | 12.808 | 22.943 | 28.221 | 37.103 | 40.291 |
Long Term Investments | |||||
Other Long Term Assets, Total | 0.483 | 0.488 | 0.488 | 0.487 | 0.488 |
Total Current Liabilities | 13.64 | 13.494 | 9.312 | 6.141 | 3.567 |
Accrued Expenses | 5.588 | 5.927 | 4.928 | 3.27 | 2.528 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22.641 | 23.842 | 20.969 | 19.049 | 12.866 |
Total Long Term Debt | 9.001 | 10.348 | 11.657 | 12.908 | 9.299 |
Other Liabilities, Total | |||||
Total Equity | -9.833 | -0.899 | 7.252 | 18.054 | 27.425 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 111.025 | 110.602 | 109.988 | 109.385 | 108.828 |
Retained Earnings (Accumulated Deficit) | -120.86 | -111.503 | -102.738 | -91.333 | -81.405 |
Total Liabilities & Shareholders’ Equity | 12.808 | 22.943 | 28.221 | 37.103 | 40.291 |
Total Common Shares Outstanding | 23.8523 | 23.851 | 23.7441 | 23.733 | 23.6086 |
Payable/Accrued | |||||
Cash & Equivalents | 6.068 | 15.74 | 22.305 | 29.685 | 31.673 |
Other Current Assets, Total | 0.406 | 0.21 | 0.062 | 0.072 | 0.264 |
Property/Plant/Equipment, Total - Net | 0.131 | 0.121 | 0.122 | 0.115 | 0.098 |
Intangibles, Net | 3.752 | 3.888 | 4.121 | 4.364 | 4.526 |
Accounts Payable | 2.513 | 3.035 | 1.255 | 1.088 | 0.735 |
Long Term Debt | 9.001 | 10.348 | 11.657 | 12.908 | 9.299 |
Current Port. of LT Debt/Capital Leases | 5.539 | 4.532 | 3.129 | 1.783 | 0.304 |
- Annual
- Quarterly
2022 | 2021 | 2020 | |
---|---|---|---|
Net income/Starting Line | -39.76 | -40.335 | -0.00169 |
Cash From Operating Activities | -28.93 | -30.818 | -0.00024 |
Changes in Working Capital | 6.268 | -2.339 | 0.00145 |
Cash From Financing Activities | 5.284 | 72.332 | 0.025 |
Financing Cash Flow Items | 0 | 62.331 | -0.06189 |
Issuance (Retirement) of Stock, Net | 0.284 | 0.001 | 0.025 |
Issuance (Retirement) of Debt, Net | 5 | 10 | 0.06189 |
Net Change in Cash | -24.826 | 40.443 | 0.02476 |
Cash From Operating Activities | 2.729 | 1.619 | |
Deferred Taxes | 0 | -0.152 | |
Non-Cash Items | 1.833 | 10.389 | |
Cash Interest Paid | 1.325 | 0.085 | |
Cash From Investing Activities | -1.18 | -1.071 | |
Capital Expenditures | -1.18 | -1.071 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.357 | -39.76 | -30.995 | -19.59 | -9.662 |
Cash From Operating Activities | -8.716 | -28.93 | -22.593 | -15.57 | -8.855 |
Non-Cash Items | 0.41 | 1.833 | 1.384 | 0.787 | 0.375 |
Changes in Working Capital | -0.524 | 6.268 | 5.01 | 1.919 | -0.231 |
Cash From Investing Activities | -0.521 | -1.18 | -0.82 | -0.457 | -0.039 |
Other Investing Cash Flow Items, Total | |||||
Cash From Financing Activities | -0.435 | 5.284 | 5.152 | 5.146 | 0.001 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0 | 0.284 | 0.152 | 0.146 | 0.001 |
Issuance (Retirement) of Debt, Net | -0.435 | 5 | 5 | 5 | |
Net Change in Cash | -9.672 | -24.826 | -18.261 | -10.881 | -8.893 |
Cash From Operating Activities | 0.755 | 2.729 | 2.008 | 1.314 | 0.663 |
Deferred Taxes | 0 | 0 | 0 | 0 | |
Cash Interest Paid | 0.495 | 1.325 | 0.87 | 0.462 | 0.219 |
Capital Expenditures | -0.521 | -1.18 | -0.82 | -0.457 | -0.039 |
Cash Taxes Paid | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Perry (David P) | Individual Investor | 53.1606 | 16868581 | 6404566 | 2023-04-12 | LOW |
Georgianna Maule-Ffinch 2015 Trust | Individual Investor | 11.4598 | 3636364 | 3636364 | 2023-04-10 | |
Appelbaum (Kevin J) | Individual Investor | 7.5847 | 2406719 | -6250 | 2023-04-10 | LOW |
Mountain Crest Capital LLC | Corporation | 4.375 | 1388250 | 0 | 2023-04-10 | LOW |
Farallon Capital Management, L.L.C. | Hedge Fund | 2.203 | 699042 | -114514 | 2023-03-31 | MED |
Armanino (Andrew J) | Individual Investor | 1.4739 | 467692 | 303030 | 2023-04-10 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.3818 | 438479 | 3700 | 2023-03-31 | LOW |
Parker (Geoffrey M) | Individual Investor | 1.2491 | 396363 | 303030 | 2023-04-10 | LOW |
Maule-Ffinch (Georgianna) | Individual Investor | 0.9238 | 293150 | 0 | 2023-04-10 | LOW |
Karbe (Frank L) | Individual Investor | 0.9216 | 292424 | 242424 | 2023-04-10 | MED |
Berman Mark A | Individual Investor | 0.7309 | 231939 | 0 | 2023-04-10 | LOW |
Carmona (Richard H. M.D.) | Individual Investor | 0.4841 | 153619 | 0 | 2023-04-10 | LOW |
Wynholds (Kristin) | Individual Investor | 0.3114 | 98819 | 0 | 2023-04-10 | LOW |
Heinen (Mark) | Individual Investor | 0.2773 | 88004 | 1 | 2023-04-10 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2523 | 80054 | 798 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.18 | 57109 | 0 | 2023-03-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.1497 | 47516 | -6473 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1424 | 45200 | 0 | 2023-03-31 | LOW |
Zamirowski (Justin) | Individual Investor | 0.1163 | 36913 | 36913 | 2022-05-27 | |
Millennium Management LLC | Hedge Fund | 0.0837 | 26556 | 14932 | 2023-03-31 | HIGH |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group530K+
Traders
87K+
Active clients monthly
$46M+
Monthly investing volume
$31M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Better Therapeutics, Inc. Company profile
About Better Therapeutics Inc
Better Therapeutics, Inc, formerly Mountain Crest Acquisition Corp II, is engaged in offering prescription digital therapeutics platform for treating cardiometabolic diseases. The Company creates treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. It builds prescription digital therapeutics that deliver a new kind of behavioral therapy and creating feedback mechanisms using remotely-monitored and patient-generated data. Its clinical development pipeline includes BT-001, BT-002, BT-003, BT-004 and BT-005. It is evaluating BT-001 in a pivotal study as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes. The Company develops Nutritional Cognitive Behavioral Therapy (Nutritional CBT), which is a novel form of behavioral therapy under development for the treatment of patients with type 2 diabetes and other cardiometabolic diseases.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Better Therapeutics Inc revenues was not reported. Net loss totaled to $550K.
Industry: | Biotechnology & Medical Research (NEC) |
548 Market St. #49404
SAN FRANCISCO
CALIFORNIA 94101
US
Income Statement
- Annual
- Quarterly
News

USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023
Gold price predictions for next 5 years: Will gold continue rising?
The yellow metal reached near record-highs, yet will it maintain the momentum and for how long?
07:50, 17 May 2023
Gold price forecast: Will gold surpass record highs?
The US debt ceiling concerns and the banking crisis have been favourable for gold, yet is there more upside potential?
12:52, 16 May 2023
Top AI stocks: What companies are leading the AI revolution?
Unravel key AI market leaders and their latest products, key AI industry trends and forecasts.
14:55, 15 May 2023People also watch
Still looking for a broker you can trust?
Join the 530.000+ traders worldwide that chose to trade with Capital.com